SC
IRWD icon

Scotia Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

Scotia Capital’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$194K Sell
55,272
-11,911
-18% -$48.8K ﹤0.01% 866
2025
Q4 		$226K Buy
+67,183
New +$174K ﹤0.01% 822

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Scotia Capital's IRWD Position: Q1 2026 in Review

Scotia Capital reduced its Ironwood Pharmaceuticals (IRWD) stake by 18% in Q1 2026, selling an estimated $48.8K and leaving 55,272 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #866.

Scotia Capital first reported a position in IRWD in Q4 2025 and has held it in 2 quarters since. The position peaked at $226K in Q4 2025. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Scotia Capital held 55,272 shares of Ironwood Pharmaceuticals worth $194K as of Q1 2026.
  • Scotia Capital sold 11,911 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $48.8K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Scotia Capital's portfolio in Q1 2026, its #866 holding.
  • Scotia Capital first reported a position in Ironwood Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Scotia Capital's Ironwood Pharmaceuticals position peaked at $226K in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.